In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection

AstraZeneca's Phase III AURA3 trial of the lung cancer drug Tagrisso was chosen for the program, Project Patient Voice. However, an FDA spokesperson said no new trials would be added in the coming weeks or months.